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L E T T E R to the Editor, 
 
Research criteria for the diagnosis of Alzheimer’s disease: genetic risk 
factors, blood biomarkers and olfactory dysfunction 
 
Dear Editor,  
 
      We note with interest the recently proposed new diagnostic framework published 
in Lancet Neurology entitled “Research criteria for the diagnosis of Alzheimer’s 
disease: revising the NINCDS-ADRDA criteria” by Dubois et al. (2007). 
We are generally positively disposed towards this framework, especially with 
regard to its emphasis (in the context of the extant scientific literature) on the 
delineation of sensitive and specific biomarkers for the diagnosis of Alzheimer’s 
disease (AD). As Norman Foster (2007) observes in his commentary piece in Lancet 
Neurology, “the NINCDS-ADRDA criteria are showing their age and risk losing their 
relevance” in the context of recent scientific evidence. However, there is a relative 
paucity of information provided by Dubois et al. (2007) in their article pertaining to 
(a) genetic risk factors and blood biomarkers for AD, and (b) the role of olfactory 
dysfunction as a potential predictor of AD. 
With respect to (a), there is now accumulating evidence in support of APOE ε4 
carriers (who represent half of all AD cases) being characterized by a different 
etiology from non- ε4 carriers (Snowden et al., 2007). An APOE ε4 gene-dosage 
effect is also present in AD, in which the risk increases from 20% when no ε4 alleles 
are present, to 90% when two copies are present.  Therefore, the associations of the ε4 
allele with AD should perhaps also be taken into consideration together with other 
factors when formulating novel diagnostic criteria for AD. Moreover, there has been a 
recent suggestion that other genetic considerations are also relevant: several studies 
have reported an association ofAD with polymorphic markers in SORL1 (e.g. 
Rogaeva et al., 2007). In addition, given their high penetrance and causal 
relationships, genetic mutations associated with early onset AD (located on 
chromosomes 1, 14, and 21) should perhaps be considered separately when assessing 
individuals where there is a strong family history of AD (St George-Hyslop, 1998). 
Blood biomarkers must also be considered given recent findings by Ray and 
colleagues (2007). These authors found that certain plasma proteins which have cell 
signaling functions can be used to classify AD and controls with up to 90% accuracy. 
The authors also suggest that analysis of these proteins from patients with mild 
cognitive impairment (MCI; i.e. pre-symptomatic AD) can be used to identify patients 
who are at risk of progressing further and developing AD. This article and other 
findings indicating that plasma levels of β amyloid are associated with increased risk 
of AD suggest that blood markers (perhaps together with genetic and cerebrospinal 
fluid markers) should be investigated as potential diagnostic biomarkers for AD. 
Furthermore, while Dubois et al. have suggested that sensory deficits should be 
considered as relevant exclusion criteria for AD, we would like to challenge this 
proposal, specifically with respect to (b), the role of olfactory dysfunction as a 
potential predictor of AD (Burns, 2000). In general terms, AD is characterized by an 
advancing wave of cortical atrophy that moves from limbic and temporal cortices into 
higher-order association and ultimately primary sensory motor areas. However, there 
is an exception to this general framework. Specifically, there is increasing evidence 
that the sensory olfactory cortex is implicated early in the progression of AD 
(Mesholam et al., 1998). Evidence for the involvement of the olfactory system is 
threefold: (i) smell dysfunction has been noted in AD patients, APOE ε4 carriers and 
family members of AD patients; (ii) MCI patients and healthy subjects showing 
cognitive decline indicative of early stage AD manifest olfactory problems; and (iii) 
there is post-mortem evidence of neurofibrillary tangles and β-amyloid plaques 
located in the olfactory system of early AD patients. Given the burgeoning literature 
regarding the involvement of the olfactory system in very early 
stage/prodromal/preclinical AD (see: Hawkes, 2006; Wilson et al., 2007), we propose 
that serious consideration should be given to the proposal that olfactory dysfunction 
should also be incorporated into a revised framework for the reliable diagnosis of AD.  
 
        In addition, specific diagnostic criteria pertaining to the potentially important 
dichotomy between familial (early onset) versus sporadic (late onset) AD – and the 
possible relevance of age at the time of diagnosis – are not clearly addressed by 
Dubois et al. 
 
        A further comment concerns the characterization of the precursor state to full-
blown AD. While the authors question the use of the term “mild cognitive 
impairment” because of its potential ambiguity, we believe that the use of the terms 
“preclinical” and “prodromal” is not clearly operationalized by Dubois et al. The use 
of these terms in the manner proposed by the authors could therefore contribute 
towards further confusion, rather than clarifying the stages preceding AD. 
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